Glamorous AI
Glamorous AI is a London-based, privately held startup founded in 2020 that develops an artificial intelligence-based drug discovery platform. The company operates with a small team (1–10 employees) and has been funded primarily through Innovate UK grants and accelerator participation.
- Company typePrivate
- Founded2020
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Glamorous AI does
Glamorous AI is a privately held, London-based company developing an artificial intelligence-based drug discovery platform. Founded in 2020, the company operates with a small team of 1–10 employees and positions itself within the AI-driven pharmaceutical R&D segment, applying machine learning techniques to the early-stage drug discovery workflow. The firm's product surface, technical architecture, and customer-facing offerings are not publicly disclosed; the company's website displays a verification/loading page, and there is no documented product, pricing, or integration footprint in the available data.
The company has been funded primarily through non-dilutive and accelerator-style capital rather than large venture rounds. Its known funding events include a £440,000 grant from Innovate UK in April 2021, participation in the MassChallenge accelerator in June 2021, and an unstated-amount round involving Cur8 Capital dated January 2023. No follow-on venture funding of meaningful scale has been disclosed in the data set. There is no information on revenue model, pricing, customer segments, or partnerships in the available source material.
Operationally, the company appears to be in an early validation phase. Leadership is anchored by co-founder Mohamed AbouZleikha, who serves as Vice President and Head of AI Product Development, suggesting AI/ML capability is core to the value proposition rather than a peripheral feature. However, with no disclosed product releases, customer logos, headcount growth, or geographic footprint beyond its London base, observable commercial traction is minimal and the company remains in pre-commercial or very early-commercial stages.
Glamorous AI firmographics
Firmographics- Name
- Glamorous AI
- Website
- https://glamorous.ai
- Company type
- Private
- Founded year
- 2020
- Headcount range
- 1–10 employees
- Short description
- Glamorous AI is a London-based, privately held startup founded in 2020 that develops an artificial intelligence-based drug discovery platform. The company operates with a small team (1–10 employees) and has been funded primarily through Innovate UK grants and accelerator participation.
- Ownership category
- akta.pro rank
Glamorous AI industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Glamorous AI is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Glamorous AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel
Glamorous AI product offering
Product offeringCore offering
Glamorous AI develops an artificial intelligence-based drug discovery platform intended to support computational drug discovery and molecular design. The company provides AI-driven tooling aimed at pharmaceutical and biotechnology researchers seeking to accelerate early-stage drug development.
Differentiator
Problem solved
Functional benefit
Products and services
- AI Drug Discovery Platform Artificial intelligence-based drug discovery platform that applies AI/ML to molecular design and early-stage pharmaceutical research, intended for pharmaceutical and biotechnology research teams.
Companies that use Glamorous AI
Customer profileIdeal customer profiles1 record
Glamorous AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Glamorous AI partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights3 records
Glamorous AI competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Glamorous AI social profiles
Digital presenceGlamorous AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Glamorous AI leadership team
Management profileNumber of profiles
Profiles1 record
Glamorous AI funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Glamorous AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Glamorous AI
What does Glamorous AI do?
Glamorous AI develops an artificial intelligence-based drug discovery platform intended to support computational drug discovery and molecular design. The company provides AI-driven tooling aimed at pharmaceutical and biotechnology researchers seeking to accelerate early-stage drug development.
When was Glamorous AI founded?
Glamorous AI was founded in 2020. It employs 1 to 10 people.
Where is Glamorous AI based?
Glamorous AI is headquartered in London, United Kingdom, in the Europe region.
Does Glamorous AI have an API?
No public API is recorded for Glamorous AI.
What industry is Glamorous AI in?
Glamorous AI's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714.